(Q33404568)

26 July 2017

1 reference

title

Alemtuzumab therapy for multiple sclerosis (English)

1 reference

26 July 2017

0 references

Alasdair J Coles

1

1 reference

26 July 2017

1 January 2013

1 reference

26 July 2017

1 reference

26 July 2017

10

1 reference

26 July 2017

1

1 reference

26 July 2017

29-33

1 reference

https://scigraph.springernature.com/pub.10.1007/s13311-012-0159-0

26 July 2017

0 references

cites work

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

CAMPATH: from concept to clinic

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

The CD52 antigen and development of the CAMPATH antibodies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Campath-1H therapy in refractory ocular inflammatory disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Reshaping human antibodies for therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Continuous cultures of fused cells secreting antibody of predefined specificity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13311-012-0159-0

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557360

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H

31 October 2018

1 reference

12 December 2020

Delayed occurrence of Graves' disease after immune restoration with HAART. Highly active antiretroviral therapy

1 reference

12 December 2020

Anti-glomerular basement membrane disease after alemtuzumab

1 reference

12 December 2020

Prevalence of incidental thyroid cancer and its ultrasonographic features in subcentimeter thyroid nodules of patients with hyperthyroidism

1 reference

12 December 2020

Relapse of Graves' disease after successful allogeneic bone marrow transplantation

1 reference

12 December 2020

10.1007/S13311-012-0159-0

Identifiers

DOI

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

PubMed ID

23184314